A novel BCR-ABL1 mutation in a patient with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia
- Citation:
- Vinhas, R, Lourenco A, Santos S, Lemos M, Ribeiro P, de Sousa AB, Baptista PV, Fernandes AR. 2018. A novel BCR-ABL1 mutation in a patient with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia, 2018. Onco Targets Ther. 11:8589-8598.
Abstract:
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) represents the most common genetic subtype of adult ALL (20%-30%) and accounts for approximately 50% of all cases in the elderly. It has been considered the subgroup of ALL with the worst outcome. The introduction of tyrosine kinase inhibitors (TKIs) allows complete hematologic remission virtually in all patients, with improved disease-free survival and overall survival. Nevertheless, the emergence of resistant mutations in BCR-ABL1 may require different TKI strategies to overcome the patient's resistance and disease relapse. Here, we report a Ph+B-ALL case with persistent minimal residual disease (MRD) after treatment with dasatinib. The patient expressed the P190(BCR-ABL1) isoform and a novel BCR-ABL1 mutation, p.Y440C. The latter is in the C-terminal lobe of the kinase domain, which likely induces deviations in the protein structure and activity and destabilizes its inactive conformation. The treatment was substituted by bosutinib, which binds to the active conformation of the protein, prior to allogeneic bone marrow transplant to overcome the lack of a complete response to dasatinib. These findings strengthen the importance of BCR-ABL1 mutational screening in Ph+ patients, particularly for those who do not achieve complete molecular remission.
Notes:
Vinhas, RaquelLourenco, Alexandra
Santos, Susana
Lemos, Marcos
Ribeiro, Patricia
de Sousa, Aida Botelho
Baptista, Pedro Viana
Fernandes, Alexandra Ramos
eng
Case Reports
New Zealand
Onco Targets Ther. 2018 Nov 30;11:8589-8598. doi: 10.2147/OTT.S177019. eCollection 2018.